The Role of Complex Karyotype in the Diagnosis of Chronic Lymphocytic Leukemia: Integration of Conventional Cytogenetics and FISH Analysis
Abstract
Complex karyotype (CK) is an emerging high-risk feature in chronic lymphocytic leukemia (CLL). We evaluated its diagnostic and prognostic relevance by integrating conventional cytogenetic analysis (CCA) and fluorescence in situ hybridization (FISH) in 30 patients. CCA identified CK in 23% of cases, including high-complexity profiles (≥5 abnormalities). FISH detected recurrent genomic lesions with established prognostic value: del(13q), trisomy 12, del(11q), del(17p). Integrated analysis improved detection of genomic complexity and refined risk stratification beyond single-lesion assessment. A representative case highlighted the ability of combined approaches to identify high-risk CK with TP53 disruption. These findings support routine integration of CCA and FISH for comprehensive cytogenetic profiling in CLL.
Downloads
References
Baliakas, P., Espinet, B., Mellink, C., Jarosova, M., Athanasiadou, A., Ghia, P., et al. (2022). Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. HemaSphere, 6(4), e707. https://doi.org/10.1097/HS9.0000000000000707
Baliakas, P., Jeromin, S., Iskas, M., et al. (2019). Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact. Blood, 133(11), 1205–1216. https://doi.org/10.1182/blood-2018-10-881698
Brenner, H., Gondos, A., & Pulte, D. (2008). Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood, 111, 4916–4921. https://doi.org/10.1182/blood-2007-10-117879
Foà, R., Del Giudice, I., Guarini, A., et al. (2013). Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica, 98(5), 675–685. https://doi.org/10.3324/haematol.2012.081828
Fürstenau, M., Thus, Y. J., Robrecht, S., Mellink, C. H. M., van der Kevie-Kersemaekers, A. M., Dubois, J., et al. (2023). High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood, 142(5), 446–459. https://doi.org/10.1182/blood.2023019634
Haferlach, C., Dicker, F., Schnittger, S., Kern, W., & Haferlach, T. (2007). Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia, 21(12), 2442–2451. https://doi.org/10.1038/sj.leu.2404935
Kamaso, J., Puiggros, A., Salido, M., Melero, C., Rodríguez-Rivera, M., Gimeno, E., et al. (2024). Complex karyotype detection in chronic lymphocytic leukemia: A comparison of parallel cytogenetic cultures using TPA and IL2+DSP30 from a single center. Cancers, 16(12), 2258. https://doi.org/10.3390/cancers16122258
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O’Brien, S., Gribben, J., & Rai, K. R. (2017). Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 3, 17008. https://doi.org/10.1038/nrdp.2017.8
Pekarsky, Y., & Croce, C. M. (2015). Role of miR-15/16 in CLL. Cell Death & Differentiation, 22(1), 6–11. https://doi.org/10.1038/cdd.2014.133
Redaelli, A., Laskin, B. L., Stephens, J. M., et al. (2004). The clinical and epidemiological burden of chronic lymphocytic leukaemia. European Journal of Cancer Care, 13, 279–287. https://doi.org/10.1111/j.1365-2354.2004.00470.x
Rigolin, G. M., Cavallari, M., Quaglia, F. M., Formigaro, L., Lista, E., Urso, A., et al. (2017). In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood, 129(26), 3495–3498. https://doi.org/10.1182/blood-2017-03-772285
Rigolin, G. M., Saccenti, E., Guardalben, E., Cavallari, M., Formigaro, L., Zagatti, B., et al. (2018). In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. British Journal of Haematology, 181(2), 229–233. https://doi.org/10.1111/bjh.15174
Rose-Zerilli, M. J., Forster, J., Parker, H., et al. (2014). ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: Data from the UK LRF CLL4 trial. Haematologica, 99(4), 736–742. https://doi.org/10.3324/haematol.2013.098574
Serafin, A., Ruocco, V., Cellini, A., Angotzi, F., Bonaldi, L., Trentin, L., et al. (2025). Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype. British Journal of Haematology, 206(3), 832–841. https://doi.org/10.1111/bjh.19986
Visentin, A., Bonaldi, L., Rigolin, G. M., Mauro, F. R., Martines, A., Frezzato, F., et al. (2022). The complex karyotype landscape in chronic lymphocytic leukemia allows refinement of the risk of Richter syndrome transformation. Haematologica. https://doi.org/10.3324/haematol.2021.280720
Visentin, A., Bonaldi, L., Rigolin, G. M., Mauro, F. R., Martines, A., Frezzato, F., et al. (2019). The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 121(2), 150–156. https://doi.org/10.1038/s41416-019-0502-x
Wan, T. S. K. (2014). Cancer cytogenetics: Methodology revisited. Annals of Laboratory Medicine, 34(6), 443–449. https://doi.org/10.3343/alm.2014.34.6.443
Wan, T. S. K. (2017). Cancer cytogenetics: Methods and protocols. Humana Press.
Woyach, J. A., Furman, R. R., Liu, T. M., et al. (2014). Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. New England Journal of Medicine, 370, 2286–2294. https://doi.org/10.1056/NEJMoa1400026
Published
How to Cite
Issue
Section
Copyright (c) 2026 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








